Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
IBS-C is an indication ripe for emerging therapies; only three drugs have a label approval for this disease across the major U.S. and European markets, although many therapies are used off-label…
An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS…
MARKET OUTLOOK The moderate to severe Crohn’s disease (CD) therapy market presents an attractive commercial opportunity for new, effective treatments. Tumor necrosis factor-alpha (TNF-α)…
Patients with osteoporosis have an increased risk of fractures owing to a loss in bone strength, which can place a considerable burden on healthcare systems. A significant unmet need exists for…
Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (…
Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. Merck & Co.’s Renflexis (…
In the last ten years, TNF-α inhibitors have transformed the treatment of axial spondyloarthritis, including ankylosing spondylitis and nonradiographic axial spondyloarthritis, and have brought…
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…
DRG Epidemiology’s coverage of diabetic macular edema (DME) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices, taking into account attributes such as…
In an attempt to mitigate postoperative pain following surgical procedures, patients may be administered analgesics/anesthetics intraoperatively, postoperatively, and at hospital discharge. Opioids…